中国将轮状病毒疫苗纳入国家免疫规划的成本效益分析
本研究构建决策树马尔可夫模型,评估2019年中国出生队列儿童普遍接种三剂轮状病毒疫苗并纳入国家免疫规划的成本效益。结果显示,纳入RotaTeq可预防5,677,911例轮状病毒感染,社会总成本净节约11亿美元;每剂17.55美元为成本节约阈值。结论认为按当前市场价格,从社会视角纳入国家免疫规划将产生显著成本。
要点
- 模型估算2019年出生队列接种三剂轮状病毒疫苗可预防5,677,911例感染。
- 纳入国家免疫规划可净节约社会总成本11亿美元。
- 每剂17.55美元为纳入国家免疫规划实现成本节约的阈值。
核心结论
- 按当前市场价格,从社会视角将轮状病毒疫苗纳入中国国家免疫规划将产生显著成本。
研究设计与样本
- 研究构建决策树马尔可夫模型,评估2019年中国出生队列儿童普遍接种三剂轮状病毒疫苗并纳入国家免疫规划的成本效益。
- 成本包括疫苗价格、疫苗损耗、接种服务及间接成本,所有成本按每年3%贴现,并按2019年汇率由2019年人民币换算为2019年美元。
主要发现
- 对2019年中国婴儿出生队列,将RotaTeq纳入国家免疫规划估计可预防5,677,911例轮状病毒感染。
- 该策略在社会总成本上净节约11亿美元。
- 每剂疫苗17.55美元是将轮状病毒疫苗纳入国家免疫规划实现成本节约的阈值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Globally, rotavirus is a leading cause of severe acute gastroenteritis among children aged under 5 years and has a significant economic cost. Currently, rotavirus vaccines are only included in the private market in China. This study aimed to assess the cost-benefit of including a three-dose rotavirus vaccine in China's National Immunization Program (NIP). METHODS: A decision tree Markov model was constructed to evaluate the cost-benefit of universal immunization with three doses of rotavirus vaccine for a 2019 birth cohort of Chinese children. Costs of the universal vaccination program included vaccine price, vaccine wastage, vaccine administration, and indirect costs. All costs were discounted at 3 % per year and converted from 2019 Chinese Yuan to 2019 USD using the 2019 exchange rate. RESULTS: For the 2019 birth cohort of Chinese infants, inclusion of RotaTeq in NIP was estimated to prevent 5,677,911 cases of rotavirus infection, with net savings of $1.1 billion in total societal costs. A cost of $17.55 per vaccine dose was the threshold at which inclusion of rotavirus vaccine in NIP would be cost-saving. CONCLUSIONS: Introducing rotavirus vaccine into the China NIP would have significant costs from a societal perspective at the current private market price.
引用
- Chen S, Gao S, Li J, et al. Cost-benefit analysis of rotavirus vaccine included in the national immunization program in China. Vaccine. 2022. PMID: 36503856. doi:10.1016/j.vaccine.2022.11.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。